1 Controls Drive
Shelton, CT 06484
203 937 6137
Full Time Employees: 17
|Dr. Anil R. Diwan Ph.D.||Exec. Chairman, Pres, CEO & Sec.||400k||N/A||1959|
|Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA||Chief Financial Officer||129.6k||N/A||1959|
|Dr. Randall W. Barton Ph.D.||Chief Scientific Officer & Chief Regulatory Officer||N/A||N/A||1947|
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.
NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.